Botolinum Toxin for the Treatment of Dysthyrolod Ocular Myopathy

William J. Dunn, Anthony C. Arnold, Patrick S. O'Connor

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Eight consecutive patients with acquired deviations due to dysthyroid ocular myopathy were injected with botulinum A toxin for relief of their diplopia. Seven patients were acute in the onset of symptoms and one was chronic. All showed improvement in motility and experienced a reduction if not total relief of their symptoms. Six patients required reinjection. Complications were limited to transient ptosis, transient involvement of adjacent muscles and transient but prolonged paralysis that eventually resolved. No systemic complications were noted. We conclude that chemodenervation with botulinum A toxin may have a role in the management of dysthyroid ocular myopathy not amenable to prism treatment and may act as an adjunct to or eliminate the need for surgical correction in some patients.

Original languageEnglish (US)
Pages (from-to)470-475
Number of pages6
Issue number4
StatePublished - 1986


  • botulinum A toxin
  • dysthyroid ocular myopathy

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Botolinum Toxin for the Treatment of Dysthyrolod Ocular Myopathy'. Together they form a unique fingerprint.

Cite this